Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 15,424 as of Tuesday, Sept. 24, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,875 issues advancing vs. 1,030 declining with 132 unchanged. The Health Care sector currently sits up 0.7% versus the S&P 500, which is up 0.2%. Top gainers within the sector include Hologic ( HOLX), up 2.6%, Teva Pharmaceutical Industries ( TEVA), up 2.2%, WellPoint ( WLP), up 1.5%, Aetna ( AET), up 1.4% and UnitedHealth Group ( UNH), up 1.3%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 1.0%, Celgene Corporation ( CELG), down 0.8%, Covidien ( COV), down 0.6% and Baxter International ( BAX), down 0.6%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Valeant Pharmaceuticals International is up $0.97 (0.9%) to $104.05 on light volume. Thus far, 465,442 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $102.45-$104.30 after having opened the day at $103.46 as compared to the previous trading day's close of $103.08. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $34.8 billion and is part of the drugs industry. Shares are up 74.7% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.